CAR-T cell therapy for CD19-positive relapsed B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new CAR-T cell therapy (a type of immune cell treatment) for patients with a specific kind of B-cell lymphoma that has come back or not responded to previous therapy. The treatment targets a protein called CD19 on the cancer cells to help your immune system fight the lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old and willing to sign a consent form.
- You have been diagnosed with a type of non-Hodgkin lymphoma that tests positive for CD19 (a protein on the cancer cells).
- Your lymphoma has come back or not responded after at least two prior treatments, including rituximab and an anthracycline drug.
- You do not have active hepatitis B, C, or HIV, and you have no serious heart or lung problems.
- Your blood counts and organ functions (kidney, liver, heart) are within safe limits as determined by tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called CD19 on your lymphoma cells. It's for people whose B-cell lymphoma has returned or not responded to standard treatments.
This trial tests a new type of CAR T-cell therapy that targets two proteins (CD20 and CD19) on your cancer cells. It is for people with certain types of lymphoma that have not responded to or have come back after at least two prior treatments.
This trial tests whether a new immune therapy (CAR-T cells) can treat certain types of blood cancers that have come back or not responded to standard treatments. It aims to help people with aggressive B-cell lymphoma or acute lymphoblastic leukemia (ALL) that hasn't been controlled by other therapies.
This trial tests a new CAR-T cell therapy (called ssCART-19) for people with B-cell lymphoma that has not responded to standard treatments or has come back. The therapy uses your own immune cells to target and kill cancer cells.
This trial tests a new type of cell therapy (CAR T) that targets two markers on lymphoma cells, CD19 and CD22. It is for people with aggressive B-cell lymphoma that has not responded to standard treatments.
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
Hear when a new Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.